Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback